Skip to Content


Active Substance: ferumoxytol
Common Name: ferumoxytol
ATC Code: B03
Marketing Authorisation Holder: Takeda Pharma A/S
Active Substance: ferumoxytol
Status: Withdrawn
Authorisation Date: 2012-06-15
Therapeutic Area: Anemia Kidney Failure, Chronic
Pharmacotherapeutic Group: Anti-anaemic preparations

Therapeutic Indication

Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).

The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).

The marketing authorisation for Rienso has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.